What drove the fivefold increase in Apr–Dec net profit?

North America was the main engine. Strong Orgovyx U.S. sales and firm Gemtesa demand lifted revenue and mix. Tight cost control helped margins, and a one‑off Asia asset sale added a non‑recurring boost. These factors combined to push nine‑month net profit to ¥107.6 billion, about five times last year.

Why did management keep FY2026 guidance unchanged?

Management balanced brand strength with caution on costs and FX. A planned Q4 R&D ramp will weigh on margins, and yen strength could reduce translated U.S. earnings. Keeping FY2026 guidance steady sets a realistic hurdle while the company protects pipeline timing and monitors currency conditions.

How weak was the October–December quarter and why?

Profit fell 84% year on year in the October–December period. Heavier R&D spending, tougher comparisons, and timing effects weighed on margins. Despite solid U.S. demand, these items offset top‑line gains. It is a reminder that investment cycles can pressure near‑term results even during broader recovery phases.

Is the stock expensive after the big run?

On earnings, not especially. The shares trade around 5.6x TTM P/E with EPS of ¥389.46. However, momentum looks overbought and cash‑flow multiples are higher, with price to FCF near 37.6x. That mix argues for patience and staged buying, especially if volatility rises after results.

Global Market Insights

4506.T Stock Today: January 31 9M Profit 5x; Full‑Year Outlook Steady

ByHuzaifa Zahoor January 30, 2026January 30, 2026

Sumitomo Pharma earnings took center stage after the company posted Apr–Dec net profit of ¥107.6 billion, about five times year on year. Strength in Orgovyx U.S. sales and Gemtesa demand, tighter costs, and a one‑off Asia asset sale supported results. Management kept FY2026 guidance unchanged, citing a planned R&D ramp in Q4 and foreign exchange risk. Latest trading shows 4506.T has surged over the past year, but near‑term momentum may cool after a soft October–December quarter. Here is what Japan‑based investors should watch next.